Subarachnoid Hemorrhage in Type 1 Diabetes

  • View
    34

  • Download
    0

Embed Size (px)

DESCRIPTION

Featured Article :. Subarachnoid Hemorrhage in Type 1 Diabetes A prospective cohort study of 4,083 patients with diabetes. Miikka Korja, M.D., P.H.D., Lena M. Thorn, M.D., P.H.D., Stefanie Hägg, M.B., - PowerPoint PPT Presentation

Text of Subarachnoid Hemorrhage in Type 1 Diabetes

  • Miikka Korja, M.D., P.H.D., Lena M. Thorn, M.D., P.H.D., Stefanie Hgg, M.B.,Jukka Putaala, M.D., P.H.D., Ron Liebkind, M.D., P.H.D., Valma Harjutsalo, P.H.D., Carol M. Forsblom, P.H.D., Daniel Gordin, M.D., P.H.D., Turgut Tatlisumak, M.D., P.H.D., Per-Henrik Groop, M.D., P.H.D., On Behalf of The FinnDiane Study Group*Diabetes Care Volume 36: 3754-3758November, 2013

  • STUDY OBJECTIVETo estimate the incidence of subarachnoid hemorrhage (SAH) in type 1 diabetesKorja M. et al. Diabetes Care 2013;36:3754-3758

  • STUDY DESIGN AND METHODSIncidence of first-ever SAH events was analyzed using the nationwide Finnish Diabetic Nephropathy (FinnDiane) Study cohort

    Korja M. et al. Diabetes Care 2013;36:3754-3758

  • RESULTSDuring the follow-up time of 36,680 person-years, 15 patients experienced an aneurysmal or nonaneurysmal SAH

    Thus, the crude incidence of SAH was 40.9 per 100,000 person-years

    One patient had a verified aneurysmal SAH

    Four patients died suddenly of an SAH, which was most likely caused by an aneurysm Korja M. et al. Diabetes Care 2013;36:3754-3758

  • RESULTS

    SAHs in 10 of 15 patients were classified as nonaneurysmal SAH

    Thus, the crude incidence of nonaneurysmal SAH was 27.3 per 100,000 person-years

    None of the nonaneurysmal SAHs were fatalKorja M. et al. Diabetes Care 2013;36:3754-3758

  • CONCLUSIONSIncidence of nonaneurysmal SAH is high among patients with type 1 diabetes

    Nonaneurysmal SAH is a distinct new microvascular complication in type 1 diabetesKorja M. et al. Diabetes Care 2013;36:3754-3758

  • Korja M. et al. Diabetes Care 2013;36:3754-3758

  • Korja M. et al. Diabetes Care 2013;36:3754-3758

  • Korja M. et al. Diabetes Care 2013;36:3754-3758

    ****Table 1- Baseline characteristics of the diabetic patients with (10 patients) and without (4,068 patients) nonaneurysmal SAH

    Continuous variables are compared withMann-Whitney U test, and the results are presented as median with IQR in parentheses. Categorical variables are compared with a x2 test, and results are presented as percentages. Timescales are reported in years. S, serum.*Table 2- Case descriptions of patients with type 1 diabetes and nonaneurysmal SAH

    ACT, anticoagulant treatment; AHT, antihypertensive treatment; AMI, acute myocardial infarction; CABG, coronary artery bypass graft; CHD, coronary heart disease;DIF, diffuse SAH; DN, diabetic nephropathy; DR, severe diabetic retinopathy; F, female; M, male; PMSAH, perimesencephalic SAH.*Table 3- Age- and sex-adjusted univariate analysis of baseline risk factors for nonaneurysmal (n = 10) and all (n = 15) SAHs in type 1 diabetes

    Hazard ratios with 95% CIs in parentheses.*